Antithrombin III

Drug Profile

Antithrombin III

Alternative Names: Antithrombin-III; Antithrombin-III-alpha; Athimbin; BI51.017; Kybernin; Kybernin P; Neuart

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics
  • Mechanism of Action Blood coagulation factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombosis
  • Preregistration Toxaemia
  • Discontinued Septic shock

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Dec 2015 Preregistration for Toxaemia in Japan (IV) prior to December 2015 (Kaketsuken pipeline, December 2015)
  • 01 Nov 2007 Regulatory review is ongoing for Toxaemia in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top